Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | BCR | P11274 | 2/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14914689 | 1.00 | ABL1 (0.38) | ABL1BCRKCNK3KCNK9NR1H2 | |
| SCHEMBL15773761 | 1.00 | ABL1 (0.38) | ABL1BCRKCNK3KCNK9NR1H2 | |
| SCHEMBL2449358 | 0.99 | ABL1 (0.38) | ABL1BCRKCNK3KCNK9NR1H2 | |
| SCHEMBL17249890 | 0.92 | USP30 (0.36) | ABL1BCRKCNK3KCNK9NR1H2 | |
| SCHEMBL17973122 | 0.91 | CYP1A2 (0.36) | KMT2AHTTUCHL1PARP1SETD7 | |
| SCHEMBL17973121 | 0.91 | CYP1A2 (0.36) | KMT2AHTTUCHL1PARP1SETD7 | |
| SCHEMBL14844685 | 0.90 | UCHL1 (0.34) | ABL1BCRUSP30HTTUCHL1 | |
| SCHEMBL14844683 | 0.90 | UCHL1 (0.34) | ABL1BCRUSP30HTTUCHL1 | |
| SCHEMBL14844703 | 0.90 | UCHL1 (0.34) | ABL1BCRUSP30HTTUCHL1 | |
| SCHEMBL1293926 | 0.89 | HTT (0.38) | NR1H2NR1H3KMT2AUSP30HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773634-B1 | ROD-LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE FRAGEMENT {2-[4-(BIPHENYL-4-YL)-1H-IMIDAZO-2-YL]PYRROLIDINE-1-CARBONLYMETHYL}AMINE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9669027-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2017015439-A1 | CRYSTALLINE FORM OF A HEPATITIS C VIRUS INHIBITOR | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-26 | — | — | WO | disclosed |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9212168-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2850075-A1 | PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2015-03-25 | — | — | EP | disclosed |
| EP-2773634-A1 | ROD -LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE FRAGEMENT {2- [4- (BI PHENYL - 4 - YL) - 1H - IMIDAZO - 2 - YL]PYRROLIDINE - 1 - CARBONLYMETHYL} AMINE | Theravance, Inc. (US) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013163262-A1 | PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | THERAVANCE, INC. (US) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013067267-A1 | ROD -LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE FRAGEMENT {2- [4- (BI PHENYL - 4 - YL) - 1H - IMIDAZO - 2 - YL] PYRROLIDINE - 1 - CARBONLYMETHYL} AMINE | THERAVANCE, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | ABL1 40/4885BCR 3807/4885KCNK3 4398/4885 |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | ABL1 40/4885BCR 3807/4885KCNK3 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.